Clinical Data 23andMe study explains variable results with obesity drugs PharmaphorumGene variants could explain why some people lose more weight than others with GLP-1 drugs, and why some are more prone to side effects.Clinical DataMetabolic & GLP-1Read full story pharminent April 9, 2026 (Last updated: April 9, 2026) Pharmaphorum Gene variants could explain why some people lose more weight than others with GLP-1 drugs, and why some are more prone to side effects. Clinical DataMetabolic & GLP-1Read full story Post navigation Previous: EverSea Medicines to acquire Hasten BiopharmaceuticalsNext: The FTC Blows Up Express Scripts’ PBM Model–and Launches the Net Pricing Drug Channel (rerun) Related Stories Clinical Data BridgeBio stands up to Pfizer in ATTR-CM as late-stage data hint at better survival pharminent May 12, 2026 Clinical Data Novo says high-dose Wegovy can cause 28% weight loss pharminent May 12, 2026 Clinical Data Pulsesight reports positive phase 1 data for PST611 in dry AMD pharminent May 11, 2026
